Profound Medical Corp. (NASDAQ: PROF) Revenue Nearly Doubles

Posted by James Quigley on Oct 9th, 2026

What happened

Profound Medical Corp. (NASDAQ: PROF) expects third-quarter revenue of $9.8 million to $10.0 million, nearly double the $5.3 million reported a year earlier. The preliminary range is also 45% to 47% above the $6.78 million Bloomberg consensus cited by the company.

The company expects gross margin to remain above 70%. Management attributed the increase to more commercial activity across its installed base and new customer accounts, but did not disclose procedure volumes or revenue mix in the update.

Why it matters

At the $9.9 million midpoint, Profound Medical Corp. (NASDAQ: PROF) added $4.6 million of revenue from a year earlier. That incremental amount equals about 46.5% of the quarter's preliminary revenue. For a company trying to turn MRI-guided, incision-free ablation into a repeat hospital procedure, the size of that step matters more than the record label.

The sequential comparison needs context. Reported second-quarter revenue was only $2.5 million, but Profound Medical Corp. (NASDAQ: PROF) said $3.1 million of shipments expected in June moved into July. Adding those shipments back creates a $5.6 million comparison base. Against that figure, the third-quarter midpoint is up about 77%, still strong but far below the reported 292% to 300% sequential increase.

The countercase is that revenue is not cash flow. Profound Medical Corp. (NASDAQ: PROF) used $19.9 million of operating cash during the first half of 2026 and held $38.3 million of cash at June 30. The preliminary update gives no operating-expense, cash-flow or site-utilization data, and the final figures could change.

Browse: stock research on every company OptimistFi covers

What's next

Full third-quarter results are scheduled after the market closes on November 5, 2026. Investors should test whether gross margin stayed above 70% and whether operating losses and cash burn narrowed. They should also look for recurring procedure revenue rather than another shipment-timing boost.

This is an evidence update, not personalized investment advice. Full results matter.

Sources

Profound Medical Corp. (NASDAQ: PROF) preliminary third-quarter 2026 revenue — Released October 7, 2026 at 4:15 p.m. ET. Preliminary revenue range, year-over-year and sequential comparisons, consensus comparison, gross-margin expectation and November 5 reporting date.
Profound Medical Corp. (NASDAQ: PROF) second-quarter 2026 results — Reported Q2 revenue, shipment timing, cash, operating cash use and revenue mix.
Profound Medical Corp. Form 8-K exhibit — SEC-furnished issuer release and verified company identity.
Photo: MRI Scanner at Narayana Multispeciality Hospital, Jaipur by GeorgeWilliams21 — Generic file photo taken May 25, 2015. It does not depict Profound Medical Corp., its products, employees or a current customer site. Original resolution 4496 by 3000 pixels.
Photo license: Creative Commons Attribution-ShareAlike 4.0 — Creator attribution: GeorgeWilliams21. Photograph used under CC BY-SA 4.0; responsive crops remain under the same license.

Read the full OptimistFi thesis on Profound Medical Corp.: https://optimistfi.com/stocks/PROF

See what would break the Profound Medical Corp. thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full Profound Medical Corp. investment case, its status and the next test to watch live on the Profound Medical Corp. thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.